Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Correction: Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma

M. A. Rajoraab, L. Dinga, M. Valicab, W. Jianga, M. Overchukab, J. Chena and G. Zheng*abc
aPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, Ontario M5G 1L7, Canada. E-mail: gzheng@uhnresearch.ca
bInstitute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College Street, Toronto, Ontario M5S 3G9, Canada
cDepartment of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada

Received 6th July 2017 , Accepted 6th July 2017

First published on 13th July 2017


Correction for ‘Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma’ by M. A. Rajora et al., Chem. Sci., 2017, DOI: 10.1039/c7sc00732a.


In Fig. 6 of the paper, the labels for the final two sets of treatment groups should be switched around as indicated in the revised figure.
image file: c7sc90047c-f6.tif
Fig. 6 In vitro evaluation of pyE-LN PDT sensitization. Cell viability was normalized to untreated cells and is presented as the average of three replicates ± standard deviation. Cells were treated with py-LN-CO (3 μM), laser (671 nm) or a combination of laser and particle. Significant differences (*p < 0.01, n = 3) were observed between treated and untreated cells, wherein significantly higher toxicity (**p < 0.01, n = 3) was observed in U87 cells versus ldlA7 cells treated with particle and laser.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.


This journal is © The Royal Society of Chemistry 2017